WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525607
CAS#: 613225-56-2
Description: F1063-0967 is a novel inhibitor of dual-specificity phosphatase 26 (DUSP26), inducing apoptosis in IMR-32 cell line.
Hodoodo Cat#: H525607
Name: F1063-0967
CAS#: 613225-56-2
Chemical Formula: C24H24N2O5S2
Exact Mass: 484.11
Molecular Weight: 484.585
Elemental Analysis: C, 59.49; H, 4.99; N, 5.78; O, 16.51; S, 13.23
Synonym: F1063-0967; F1063 0967; F10630967; F-10630967; F 10630967;
IUPAC/Chemical Name: (Z)-2-Hydroxy-4-{6-[5-(4-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-hexanoylamino}-benzoic acid
InChi Key: RNICWTYEMLCCAS-MOSHPQCFSA-N
InChi Code: InChI=1S/C24H24N2O5S2/c1-15-6-8-16(9-7-15)13-20-22(29)26(24(32)33-20)12-4-2-3-5-21(28)25-17-10-11-18(23(30)31)19(27)14-17/h6-11,13-14,27H,2-5,12H2,1H3,(H,25,28)(H,30,31)/b20-13-
SMILES Code: O=C(O)C1=CC=C(NC(CCCCCN(C/2=O)C(SC2=C/C3=CC=C(C)C=C3)=S)=O)C=C1O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | F1063-0967 is a Dual-specificity phosphatase 26 (DUSP26) inhibitor with an IC50 of 11.62 μM. |
In vitro activity: | The inhibitory activity of F1063-0967 against DUSP26 is higher than that of NCS87877 (IC50 value: 16.67±2.89μM), but lower than that of ethyl-3, 4-dephostatin (IC50 value: 6.8±0.41μM). MTT assay results revealed that F1063-0967 can induce apoptosis in IMR-32 cell line with an IC50 value of 4.13μM. Reference: Biomed Pharmacother. 2017 May;89:376-385. https://pubmed.ncbi.nlm.nih.gov/28249240/ |
In vivo activity: | TBD |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 100.0 | 206.36 |
The following data is based on the product molecular weight 484.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | 1. Ren JX, Cheng Z, Huang YX, Zhao JF, Guo P, Zou ZM, Xie Y. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385. doi: 10.1016/j.biopha.2017.02.064. Epub 2017 Feb 27. PMID: 28249240. |
In vitro protocol: | 1. Ren JX, Cheng Z, Huang YX, Zhao JF, Guo P, Zou ZM, Xie Y. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385. doi: 10.1016/j.biopha.2017.02.064. Epub 2017 Feb 27. PMID: 28249240. |
In vivo protocol: | TBD |
1: Ren JX, Cheng Z, Huang YX, Zhao JF, Guo P, Zou ZM, Xie Y. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385. doi: 10.1016/j.biopha.2017.02.064. Epub 2017 Feb 27. PubMed PMID: 28249240.